SINGLE FIBER EMG AS A PROGNOSTIC TOOL IN MYASTHENIA GRAVIS

被引：22

作者：

Baruca, Mateja ^{[1
]}

Leonardis, Lea ^{[2
]}

Podnar, Simon ^{[2
]}

Hojs-Fabjan, Tanja ^{[3
]}

Grad, Anton ^{[4
]}

Jerin, Ales ^{[5
]}

Blagus, Rok ^{[6
]}

Sega-Jazbec, Sasa ^{[1
]}

机构：

[1] Univ Med Ctr Ljubljana, Dept Neurol, Zaloska Cesta 2, Ljubljana 1000, Slovenia

[2] Univ Med Ctr Ljubljana, Inst Clin Neurophysiol, Ljubljana, Slovenia

[3] Univ Med Ctr Maribor, Dept Neurol, Maribor, Slovenia

[4] Gen Hosp Isola, Isola, Slovenia

[5] Univ Med Ctr Ljubljana, Clin Inst Clin Chem & Biochem, Ljubljana, Slovenia

[6] Univ Ljubljana, Inst Biostat & Med Informat, Fac Med, Ljubljana, Slovenia

来源：

MUSCLE & NERVE | 2016年 / 54卷 / 06期

关键词：

jitter; myasthenia gravis; orbicularis oculi muscle; outcome; prognosis; single fiber electromyography; CONCENTRIC NEEDLE ELECTRODES; OCULAR MYASTHENIA; EXTRAOCULAR-MUSCLE; JITTER; ANTIBODY; ELECTROMYOGRAPHY; RECOMMENDATIONS; VALUES;

D O I：

10.1002/mus.25174

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Introduction: Single fiber electromyography (SFEMG) is the most sensitive diagnostic tool for diagnosis of myasthenia gravis (MG). Its prognostic value is not known. Methods: We retrospectively analyzed the clinical course of 232 MG patients who presented with only mild symptoms and had SFEMG of the orbicularis oculi muscle. We correlated their SFEMG results with the severity of their later clinical course. Results: During the observation period 39 patients (17%) developed severe disease exacerbations, and 193 (83%) remained stable. Patients with severe disease exacerbation had a significantly higher mean jitter value (P < 0.0001), a greater percentage of fibers with increased jitter (P < 0.0001), and/or impulse blocking (P < 0.0001) on SFEMG. Conclusions: The extent of the SFEMG abnormalities in this study correlated with the later clinical course of MG.

引用

页码：1034 / 1040

页数：7

共 34 条

[1] LATE-ONSET MYASTHENIA GRAVIS: A REVIEW WHEN INCIDENCE IN OLDER ADULTS KEEPS INCREASING
Alkhawajah, Nuha M.
Oger, Joel
[J]. MUSCLE & NERVE, 2013, 48 (05) : 705 - 710
[2] A systematic review of diagnostic studies in myasthenia gravis
Benatar, Michael
[J]. NEUROMUSCULAR DISORDERS, 2006, 16 (07) : 459 - 467
[3] Prognostic factors for exacerbations and emergency treatments in myasthenia gravis
de Meel, Robert H. P.
Lipka, Alexander F.
van Zwet, Erik W.
Niks, Erik H.
Verschuuren, Jan J. G. M.
[J]. JOURNAL OF NEUROIMMUNOLOGY, 2015, 282 : 123 - 125
[4] Myasthenia gravis: subgroup classification and therapeutic strategies
Gilhus, Nils Erik
Verschuuren, Jan J.
[J]. LANCET NEUROLOGY, 2015, 14 (10) : 1023 - 1036
[5] Lifetime course of myasthenia gravis
Grob, David
Brunner, Norman
Namba, Tatsuji
Pagala, Murali
[J]. MUSCLE & NERVE, 2008, 37 (02) : 141 - 149
[6] HOWARD JF, 1981, MUSCLE NERVE, V4, P254
[7] Myasthenia gravis - Recommendations for clinical research standards
Jaretzki, A
Barohn, RJ
Ernstoff, RM
Kaminski, HJ
Keesey, JC
Penn, AS
Sanders, DB
[J]. NEUROLOGY, 2000, 55 (01) : 16 - 23
[8] Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis
Kaminski, HJ
Li, ZY
Richmonds, C
Lin, F
Medof, ME
[J]. EXPERIMENTAL NEUROLOGY, 2004, 189 (02) : 333 - 342
[9] Kapinas K, 1999, INT J IMMUNOPATH PH, V12, P127
[10] KONISHI T, 1981, NEUROLOGY, V31, P386

← 1 2 3 4 →